Your browser is no longer supported. Please, upgrade your browser.
Settings
SGEN Seattle Genetics, Inc. daily Stock Chart
SGEN [NASD]
Seattle Genetics, Inc.
Index- P/E- EPS (ttm)-1.75 Insider Own1.10% Shs Outstand165.10M Perf Week20.21%
Market Cap12.54B Forward P/E- EPS next Y-0.54 Insider Trans-8.78% Shs Float160.27M Perf Month5.87%
Income-279.80M PEG- EPS next Q-0.36 Inst Own- Short Float6.07% Perf Quarter7.40%
Sales757.60M P/S16.55 EPS this Y-61.10% Inst Trans5.11% Short Ratio11.08 Perf Half Y7.35%
Book/sh8.18 P/B9.28 EPS next Y59.70% ROA-14.30% Target Price80.15 Perf Year8.10%
Cash/sh2.53 P/C29.98 EPS next 5Y23.00% ROE-16.70% 52W Range50.71 - 84.37 Perf YTD34.05%
Dividend- P/FCF- EPS past 5Y-22.40% ROI-18.60% 52W High-9.98% Beta2.04
Dividend %- Quick Ratio2.90 Sales past 5Y19.40% Gross Margin90.20% 52W Low49.77% ATR2.91
Employees1302 Current Ratio3.30 Sales Q/Q38.80% Oper. Margin-34.30% RSI (14)62.13 Volatility4.31% 3.81%
OptionableYes Debt/Eq0.00 EPS Q/Q88.70% Profit Margin-29.40% Rel Volume0.85 Prev Close76.07
ShortableYes LT Debt/Eq0.00 EarningsJul 16 AMC Payout- Avg Volume878.29K Price75.95
Recom2.20 SMA209.85% SMA5010.82% SMA20011.85% Volume746,824 Change-0.16%
Jul-18-19Initiated Deutsche Bank Hold $79
Jul-17-19Upgrade Piper Jaffray Neutral → Overweight $64 → $75
Apr-11-19Initiated Stifel Hold $70
Mar-27-19Initiated Berenberg Buy $95
Oct-26-18Reiterated Barclays Overweight $95 → $90
Oct-26-18Downgrade BofA/Merrill Neutral → Underperform
Sep-25-18Initiated Leerink Partners Outperform
Sep-07-18Resumed Piper Jaffray Neutral
Jul-30-18Reiterated Needham Buy $74 → $79
Jul-27-18Reiterated H.C. Wainwright Buy $77 → $98
Jun-11-18Upgrade SunTrust Hold → Buy
Mar-20-18Resumed Barclays Overweight $74
Feb-14-18Upgrade JP Morgan Neutral → Overweight
Feb-07-18Reiterated Needham Buy $72 → $74
Nov-13-17Reiterated RBC Capital Mkts Outperform $68 → $69
Oct-27-17Upgrade BofA/Merrill Underperform → Neutral
Oct-24-17Resumed Guggenheim Buy $72
Oct-20-17Upgrade Barclays Equal Weight → Overweight $60 → $70
Oct-06-17Resumed Goldman Neutral
Sep-15-17Initiated RBC Capital Mkts Outperform $58
Jul-23-19 10:26PM  Seattle Genetics Announces Pricing of Public Offering of Common Stock Business Wire
04:09PM  Seattle Genetics Announces Proposed Public Offering of Common Stock Business Wire
07:41AM  Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More Benzinga
07:31AM  Seattle Genetics Has a Rally in Its DNA TheStreet.com
03:03AM  3 Perfect 10 Biotech Stocks to Buy TipRanks
Jul-18-19 05:07PM  Edited Transcript of SGEN earnings conference call or presentation 16-Jul-19 8:30pm GMT Thomson Reuters StreetEvents
02:41PM  Seattle Genetics Hits Its Second Growth Phase Motley Fool
Jul-17-19 04:26PM  Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today Motley Fool +18.98%
12:20PM  Here's Why Seattle Genetics Rocketed Higher Today Motley Fool
10:58AM  Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates Zacks
01:23AM  Seattle Genetics Inc (SGEN) Q2 2019 Earnings Call Transcript Motley Fool
Jul-16-19 05:25PM  Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:13PM  The Surprising Reason This Biotech Stock Got An After-Hours Boost Investor's Business Daily
04:02PM  Seattle Genetics Reports Second Quarter 2019 Financial Results Business Wire
02:30PM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
08:00AM  Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM  Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Jul-13-19 05:04PM  The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings Benzinga
08:01AM  Brief Commentary On Seattle Genetics, Inc.'s (NASDAQ:SGEN) Fundamentals Simply Wall St.
Jul-10-19 08:15PM  Seattle Genetics Inc (SGEN) President and CEO Clay B Siegall Sold $1.3 million of Shares GuruFocus.com -5.21%
Jul-09-19 10:30AM  Earnings Preview: Seattle Genetics (SGEN) Q2 Earnings Expected to Decline Zacks
Jul-02-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019 Business Wire
Jun-24-19 09:00AM  Natasha A. Hernday Elected to PDL BioPharma's Board of Directors PR Newswire
Jun-20-19 07:16PM  Clay Siegall continues Seattle Genetics' fast expansion, growth American City Business Journals
Jun-19-19 06:00PM  Heres What Hedge Funds Think About Seattle Genetics, Inc. (SGEN) Insider Monkey
Jun-18-19 08:03AM  Roche's Rozlytrek Gets Approval in Japan for Solid Tumors Zacks
Jun-17-19 09:51AM  Does Seattle Genetics, Inc.'s (NASDAQ:SGEN) CEO Salary Compare Well With Others? Simply Wall St.
Jun-12-19 08:00AM  Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (ICML) Business Wire
Jun-11-19 09:54AM  Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II Zacks
Jun-10-19 12:51PM  Seattle Genetics Antibody-Drug Conjugate Technology Utilized in Genentechs Polivy, Now Approved by FDA Business Wire
Jun-04-19 05:30PM  Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR Zacks
Jun-03-19 04:24PM  Who Are The Winners And Losers From The Year's Biggest Cancer Meeting? Investor's Business Daily
11:22AM  Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study Reuters
09:22AM  Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study Reuters
08:00AM  Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting Business Wire
07:30AM  Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer Business Wire
07:30AM  Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer PR Newswire
Jun-01-19 11:37AM  The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace Benzinga
May-29-19 08:36PM  Revealed: PSBJ inaugural Middle Market Fast 50 list makers American City Business Journals
May-25-19 09:31AM  Seattle Genetics (SGEN) Down 2.7% Since Last Earnings Report: Can It Rebound? Zacks
May-21-19 08:00AM  Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer Business Wire
May-15-19 05:10PM  Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire
03:36PM  Seattle Genetics, Inc. (NASDAQ:SGEN): Financial Strength Analysis Simply Wall St.
08:00AM  Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference Business Wire
May-03-19 12:09PM  Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada Business Wire
May-01-19 04:47AM  Edited Transcript of SGEN earnings conference call or presentation 25-Apr-19 8:30pm GMT Thomson Reuters StreetEvents
Apr-30-19 07:00PM  Top Biotech Stocks for February 2019 Investopedia
03:53PM  Seattle Genetics' "Growth Is Tracking Well" Motley Fool
Apr-26-19 01:11PM  Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark Zacks
10:48AM  SEATTLE GENETICS INC (SGEN) Q1 2019 Earnings Call Transcript Motley Fool
08:02AM  The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug Benzinga
Apr-25-19 04:08PM  Seattle Genetics: 1Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports First Quarter 2019 Financial Results Business Wire
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
02:30AM  Seattle Genetics, Inc. to Host Earnings Call ACCESSWIRE
Apr-18-19 07:22PM  Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)? Insider Monkey
10:33AM  Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-11-19 02:48PM  Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified? Simply Wall St.
09:53AM  Seattle Genetics' Adcetris Progresses Well Amid Competition Zacks
Apr-10-19 01:40PM  5 Oncology Companies That Are Set to Run GuruFocus.com
Apr-08-19 08:45AM  Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher Zacks
Apr-04-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019 Business Wire
Apr-01-19 10:49AM  Seattle Genetics Closes Enrollment in Cervical Cancer Study Zacks
Mar-29-19 01:57PM  Seattle Genetics, Astellas Report Positive Cancer Study Data Zacks
08:00AM  Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer Business Wire
Mar-28-19 04:31PM  This Biotech Stock Toppled Despite Success In Bladder Cancer Study Investor's Business Daily
07:00AM  Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin Business Wire
03:01AM  Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Mar-27-19 08:00AM  Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting Business Wire
Mar-09-19 09:31AM  Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-06-19 12:22PM  ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates GuruFocus.com
06:42AM  Pullback Strategies: 10 Stocks That Could Fall the Fastest Investopedia
Mar-05-19 11:32AM  Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic? Simply Wall St.
08:00AM  Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference Business Wire
Mar-04-19 09:46PM  Seattle Genetics' new Bothell campus sells for $63M American City Business Journals
Feb-14-19 10:38AM  Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored Bloomberg
Feb-13-19 03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
07:35AM  New Research: Key Drivers of Growth for Phillips 66, Seattle Genetics, Green Plains, C&J Energy Services, FRP, and Medical Transcription Billing Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-12-19 09:29PM  Edited Transcript of SGEN earnings conference call or presentation 7-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
05:30PM  Seattle Genetics' Adcetris Gets EC Nod for Label Expansion Zacks
Feb-11-19 08:00AM  Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma Business Wire
Feb-08-19 04:58PM  Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today Motley Fool -11.84%
04:14PM  Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'? Investor's Business Daily
03:58PM  Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark Zacks
03:24PM  Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed Motley Fool
01:17PM  Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:17AM  The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga
Feb-07-19 05:55PM  Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates Zacks
05:00PM  Seattle Genetics: 4Q Earnings Snapshot Associated Press
04:02PM  Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
11:54AM  Stocks Moving After Hours: Mattel, Skechers, Columbia Sports Investing.com
Feb-06-19 08:00AM  Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day Business Wire
Feb-04-19 09:09AM  What's in the Cards for Glaxo (GSK) This Earnings Season? Zacks
08:58AM  Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? Zacks
Jan-31-19 10:31AM  Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks
Jan-22-19 08:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019 Business Wire
Jan-16-19 08:01AM  Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Have Been Selling Simply Wall St.
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-09-19 08:00AM  Seattle Genetics Announces Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma Business Wire
Jan-02-19 08:54AM  Seattle Genetics-occupied Bothell property fetches $34 million American City Business Journals
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRYSKA DAVID WDirectorJul 17Option Exercise12.765,00063,80053,013Jul 19 06:20 PM
GRYSKA DAVID WDirectorJul 17Sale75.005,000375,00048,013Jul 19 06:20 PM
SIEGALL CLAY BPresident and CEOJul 08Option Exercise12.1620,148245,000761,011Jul 10 06:57 PM
SIEGALL CLAY BPresident and CEOJul 08Sale66.8920,1481,347,664746,294Jul 10 06:57 PM
HIMES VAUGHN BChief Technical OfficerJun 24Option Exercise42.514,704199,970182,033Jun 26 06:26 PM
DANSEY ROGER DChief Medical OfficerJun 17Sale68.605,416371,53877,593Jun 19 06:43 PM
SIEGALL CLAY BPresident and CEOJun 10Option Exercise12.1620,148245,000760,119Jun 12 05:51 PM
SIEGALL CLAY BPresident and CEOJun 10Sale69.0520,1481,391,175749,169Jun 12 05:51 PM
HIMES VAUGHN BChief Technical OfficerMay 31Option Exercise12.008,00096,000185,329Jun 04 06:28 PM
HIMES VAUGHN BChief Technical OfficerMay 31Sale65.948,000527,485177,329Jun 04 06:28 PM
SIEGALL CLAY BPresident and CEOMay 09Option Exercise12.164,82458,660752,063May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 09Sale67.434,824325,301749,169May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Option Exercise12.1615,324186,340762,600May 10 04:39 PM
SIEGALL CLAY BPresident and CEOMay 08Sale68.2615,3241,046,066749,169May 10 04:39 PM
BAKER BROS. ADVISORS LPDirectorApr 29Option Exercise8.3820,000167,60045,839,686May 01 04:59 PM
SIEGALL CLAY BPresident and CEOApr 08Option Exercise12.1620,148245,000757,976Apr 10 04:39 PM
SIEGALL CLAY BPresident and CEOApr 08Sale79.2220,1481,596,100749,169Apr 10 04:39 PM
SIMPSON TODD EChief Financial OfficerApr 05Sale78.0012,500975,000171,780Apr 09 08:35 PM
GRYSKA DAVID WDirectorApr 01Option Exercise12.765,00063,80050,050Apr 03 08:57 PM
GRYSKA DAVID WDirectorApr 01Sale73.415,000367,03045,050Apr 03 08:57 PM
SIEGALL CLAY BPresident and CEOMar 18Option Exercise12.0816,556199,988749,169Mar 20 06:34 PM
SIEGALL CLAY BPresident and CEOMar 08Option Exercise12.1620,148245,000745,259Mar 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Option Exercise12.008,00096,000185,329Mar 12 07:31 PM
SIEGALL CLAY BPresident and CEOMar 08Sale69.1920,1481,394,094732,613Mar 12 07:34 PM
HIMES VAUGHN BChief Technical OfficerMar 08Sale68.728,000549,746177,329Mar 12 07:31 PM
SIMPSON TODD EChief Financial OfficerMar 04Sale75.0010,000750,000184,280Mar 06 06:58 PM
SIEGALL CLAY BSee RemarksFeb 08Option Exercise12.1620,148245,000740,690Feb 12 06:25 PM
SIEGALL CLAY BSee RemarksFeb 08Sale65.1720,1481,313,126732,613Feb 12 06:25 PM
GRYSKA DAVID WDirectorJan 08Option Exercise12.765,00063,80050,050Jan 10 09:09 PM
SIEGALL CLAY BPresident and CEOJan 08Option Exercise12.1620,148245,000739,713Jan 10 08:27 PM
SIEGALL CLAY BPresident and CEOJan 08Sale65.7320,1481,324,237732,613Jan 10 08:27 PM
GRYSKA DAVID WDirectorJan 08Sale65.045,000325,20045,050Jan 10 09:09 PM
SIEGALL CLAY BPresident and CEODec 10Option Exercise12.1620,148245,000745,761Dec 12 07:31 PM
SIEGALL CLAY BPresident and CEODec 10Sale59.7420,1481,203,545732,613Dec 12 07:31 PM
HIMES VAUGHN BChief Technical OfficerNov 30Option Exercise12.005,00060,000177,329Dec 04 07:37 PM
HIMES VAUGHN BChief Technical OfficerNov 30Sale62.145,000310,718172,329Dec 04 07:37 PM
Cline Darren SEVP, CommercialNov 29Sale62.887,000440,16072,556Nov 30 06:32 PM
Cline Darren SEVP, CommercialNov 21Sale56.684,167236,20479,556Nov 21 06:42 PM
SIEGALL CLAY BPresident and CEONov 08Option Exercise12.1620,148245,000746,091Nov 09 05:54 PM
SIEGALL CLAY BPresident and CEONov 08Sale61.5420,1481,239,873732,613Nov 09 05:54 PM
AKKARAJU SRINIVASDirectorOct 30Option Exercise8.385,00041,90037,205Nov 01 05:55 PM
SIEGALL CLAY BPresident and CEOOct 08Option Exercise12.1620,148245,000746,550Oct 09 08:13 PM
SIEGALL CLAY BPresident and CEOOct 08Sale77.3920,1481,559,231732,613Oct 09 08:13 PM
SIEGALL CLAY BPresident and CEOSep 17Option Exercise12.1620,148245,000742,544Sep 19 06:36 PM
SIEGALL CLAY BPresident and CEOSep 17Sale76.8420,1481,548,196732,613Sep 19 06:36 PM
HIMES VAUGHN BChief Technical OfficerSep 07Option Exercise12.005,00060,000182,329Sep 11 07:26 PM
HIMES VAUGHN BChief Technical OfficerSep 07Sale76.995,000384,962177,329Sep 11 07:26 PM
SIMPSON TODD EChief Financial OfficerAug 27Sale74.235,427402,856173,565Aug 29 07:40 PM
SIEGALL CLAY BPresident and CEOAug 27Sale74.2325,5141,893,950636,632Aug 29 07:39 PM
LIU JEAN IGC/EVP, Leg AffairsAug 27Sale74.234,123306,05856,741Aug 29 07:37 PM
HIMES VAUGHN BChief Technical OfficerAug 27Sale74.235,530410,502159,376Aug 29 07:35 PM
Cline Darren SEVP, CommercialAug 27Sale74.234,784355,12565,079Aug 29 07:32 PM
SIEGALL CLAY BPresident and CEOAug 21Sale74.9525,0001,873,750662,146Aug 23 08:01 PM
SIEGALL CLAY BSee RemarksAug 09Option Exercise11.0918,831208,836703,857Aug 13 04:47 PM
SIEGALL CLAY BSee RemarksAug 09Sale72.7118,8311,369,153687,146Aug 13 04:47 PM
LIPPMAN MARC EDirectorJul 31Sale69.257,400512,450128,350Aug 02 08:00 PM